<DOC>
	<DOCNO>NCT01045603</DOCNO>
	<brief_summary>The aim study describe use Instanyl® ( Intranasal fentanyl spray ) treatment breakthrough pain ( BTP ) cancer patient success dose titration distribution dose strength . Data collect three different time point 3 month period .</brief_summary>
	<brief_title>Instanyl® Non-Interventional Study</brief_title>
	<detailed_description />
	<criteria>Adult cancer patient suffer BTP Instanyl prescribe accordance Summary Product Characteristics ( SPC ) none state contradiction apply The decision prescribe make independently study All patient must provide sign Informed Consent prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Instanyl</keyword>
	<keyword>non-interventional</keyword>
	<keyword>breakthrough cancer pain</keyword>
	<keyword>BTP</keyword>
	<keyword>BTCP</keyword>
	<keyword>Intranasal fentanyl spray</keyword>
</DOC>